FMS Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Revenue Growth: Achieved solid organic group revenue growth of 5% (4% at constant currency), with all three operating segments contributing positively.
Operating Income: Increased by 23% at constant currency, driven by Care Delivery and Value-Based Care segments.
Operating Margin: Expanded by 180 basis points, reflecting improved profitability across segments.
Cash Flow: Operating cash flow grew by 11%, while free cash flow remained stable at EUR 625 million.
Share Buyback: Completed an initial EUR 1 billion share buyback program and launched a second EUR 1 billion program.
Net Leverage Ratio: Maintained at 2.6x, at the lower end of the target corridor.

2. Strategic Updates and Business Highlights

FME25+ Transformation Program: Delivered EUR 67 million in sustainable savings during the quarter, contributing to margin expansion.
Care Delivery: Despite a 0.9% decline in U.S. same-market treatment growth, international markets showed 0.8% growth. Focus on quality care led to improvements in missed treatments and mortality rates.
Value-Based Care: Revenue grew by 9%, with operating income improving significantly from a loss to EUR 18 million.
Care Enablement: Organic revenue growth of 3%, with challenges in China due to regulatory changes, but positive momentum outside China.
5008X Rollout: Continued acceleration in U.S. clinics, with 10% of machines converted and positive early patient feedback.

3. Forward Guidance and Outlook

Revenue Expectations: Anticipate broadly flat revenue development for the full year, with operating income expected to remain at elevated levels.
U.S. Treatment Growth: Revised expectations for U.S. same-market treatment growth in 2026 to align with Q2 levels due to referral dynamics.
TDAPA Impact: Expect a lower year-over-year headwind of around EUR 50 million compared to previous estimates of EUR 100 million.

4. Challenges and Points of Concern

Referral Issues: Identified an operational miss in capturing referrals, leading to a decline in U.S. treatment growth. Organizational changes are being implemented to address this gap.
China Market: Regulatory pressures continue to pose challenges, with a EUR 20 million headwind in Q2. Expected normalization in the second half of the year.
Inflationary Pressures: Elevated raw material and logistics costs due to geopolitical conflicts are being monitored closely, impacting Care Enablement.

5. Notable Q&A Insights

Referral Dynamics: Management acknowledged a significant decline in referrals and emphasized the need for improved business development strategies to capture fair market share.
TDAPA Contributions: Clarified that TDAPA benefits would shift from positive to negative in the second half of the year, impacting overall earnings.
Clinic Closures: While 100 clinics were closed, management indicated that further closures would be considered based on future volume trends and profitability.
International Growth: The decline in international same-market treatment growth was attributed to market exits and mix effects rather than fundamental issues.

Overall, FMS reported a strong second quarter with solid financial performance but faces challenges in U.S. treatment growth and external pressures in certain markets. The company is focused on addressing operational gaps and maintaining profitability amid changing market conditions.

FMS — Fresenius Medical Care AG & Co. KGaA